Live tape
Top 8, mentions 7d9,824TSLA2,036 mentions▲ +0.05GOOGL1,581 mentions▲ +0.04NVDA1,205 mentions▲ +0.07CRWV1,185 mentions▲ +0.03SPCX1,067 mentions▲ +0.07QQQ1,041 mentions▲ +0.04META870 mentions▲ +0.05NBIS839 mentions▲ +0.05

Equity

FOLD

Amicus Therapeutics

Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for FOLD to draw a line in its place.

Track this symbol on TradingView TradingView chart

FOLD insider trades

SEC Form 4

FOLD has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 1 December 2025.

Date Insider Type Shares Value
01 Dec 2025 Campbell Bradley L President and CEO Sell 14,587 $146K
26 Nov 2025 Rosenberg Ellen Chief Legal Officer Sell 23,621 $236K
25 Nov 2025 Rosenberg Ellen Chief Legal Officer Sell 36,000 $360K
24 Nov 2025 Campbell Bradley L President and CEO Sell 14,587 $147K
24 Nov 2025 Clark David Michael Chief People Officer Sell 25,643 $259K
24 Nov 2025 Castelli Jeff Chief Development Officer Sell 76,158 $774K
24 Nov 2025 Rosenberg Ellen Chief Legal Officer Sell 36,000 $362K
04 Nov 2025 Clark David Michael Chief People Officer Sell 25,643 $244K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Dec 2025 Prout Samantha Chief Accounting Officer Award 32,193
01 Dec 2025 Campbell Bradley L President and CEO Option exercise 14,587 $132K
26 Nov 2025 Rosenberg Ellen Chief Legal Officer Option exercise 23,621 $121K
25 Nov 2025 Rosenberg Ellen Chief Legal Officer Option exercise 36,000 $185K
24 Nov 2025 Campbell Bradley L President and CEO Option exercise 14,587 $132K
24 Nov 2025 Castelli Jeff Chief Development Officer Option exercise 50,000 $452K
24 Nov 2025 Rosenberg Ellen Chief Legal Officer Option exercise 36,000 $209K

FOLD earnings

SEC EDGAR
Date Period EPS Revenue
31 Dec 2025 FY 2025 −$0.09 —
30 Sep 2025 Q3 2025 $0.06 —
30 Jun 2025 Q2 2025 −$0.08 —
31 Mar 2025 Q1 2025 −$0.07 —
31 Dec 2024 FY 2024 −$0.18 —
30 Sep 2024 Q3 2024 −$0.02 —
30 Jun 2024 Q2 2024 −$0.05 —
31 Mar 2024 Q1 2024 −$0.16 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

FOLD institutional holders

SEC Form 13F SEC EDGAR

0 of the 45 institutional funds we track reported a FOLD position for the quarter ended 30 Jun 2026; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Exited
Balyasny Asset Management Exited
Citadel Advisors Exited
D. E. Shaw & Co. Exited
GAMCO Investors Exited
Man Group Exited
Marshall Wace Exited
Millennium Management Exited
Point72 Asset Management Exited
Renaissance Technologies Exited

Congressional trades in FOLD

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in FOLD is a sale by Daniel S. Goldman (house, NY), dated 10 Apr 2023.

Date Member Type Amount
10 Apr 2023 filed 19 May 2023 Daniel S. Goldman house · Democrat–NY Sale $1K–$15K

Sources

  1. TradingViewthe price chart widget, drawn by TradingView from their own data
  2. SEC EDGARSEC EDGAR 13F filings
  3. House disclosuresU.S. House of Representatives financial disclosures
  4. Wikipediatext of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Amicus_Therapeutics